NASDAQ
10.94USD
+0.93 (+9.29%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2B
P/E
—
EPS
—
Beta
2.42
52W range
1.39-15.88
Day range
9.80–10.99
Open
10.00
Prev close
10.01
Volume
3.9M
Avg volume
9.7M
Dividend
0.00
IPO
2008-03-12
https://seekingalpha.com/article/4929311-sellas-life-sciences-the-ownership-structure-has-changed-before-the-defining-catalyst · 8/2/2026+0.80
https://www.benzinga.com/markets/equities/26/05/52865133/jim-cramer-buy-ge-aerospace-two-thumbs-up-for-this-life-sciences-stock · 5/29/2026+1.00
https://www.benzinga.com/news/health-care/26/03/51044289/whats-going-with-sellas-life-sciences-stock-on-wednesday · 3/4/2026+1.00
https://www.globenewswire.com/news-release/2025/12/29/3210926/0/en/SELLAS-Life-Sciences-Provides-Update-on-Pivotal-Phase-3-REGAL-Trial-of-Galinpepimut-S-GPS-in-Acute-Myeloid-Leukemia-AML.html · 12/29/2025+0.30
https://www.globenewswire.com/news-release/2025/12/07/3201154/0/en/SELLAS-Life-Sciences-Presents-Positive-Phase-2-Data-of-SLS009-in-Combination-with-AZA-VEN-in-Relapsed-Refractory-AML-MR-at-ASH-2025.html · 12/7/2025+1.00
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
